MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer
Source abstract
Abstract
It has been demonstrated that circulating MicroRNAs (miRNAs) could be potential biomarkers for cancer diagnosis and prognosis. For pancreatic cancer (PCa), little is known about miR-221-3p biological function or its prognostic value. In the current study, we profiled miR-221-3p expression in PCa cell lines. Compared with normal pancreases ductal epithelial cells, miR-221-3p is up-regulated in all PCa cell lines analysed. In SW1990 cells, overexpression of miR-221-3p increased cell proliferation and inhibited apoptosis, while inhibition of miR-221-3p decreased cell growth rate and promoted apoptosis. Compared with adjacent non-tumour tissues, miR-221-3p was up-regulated in all 21 PCa tissues. Expression level of miR-221-3p was investigated in plasma and statistical analyses showed that circulating miR-221-3p expression level was correlated with distant metastasis and TNM stages. The receiver-operating characteristic (ROC) curves and the area under the ROC curve (AUC) suggested that the diagnostic efficacy for distant metastasis of miR-221-3p is better than CA19-9 (AUC: 0.689 vs. 0.587). To summary, we found miR-221-3p could promote cell proliferation and inhibit apoptosis in PCa cells and circulating miR-221-3p could serve as a biomarker for PCa.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Cancer-related molecular mechanisms research · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China;
Departments of Ultrasound and Radiology, Provincial Hospital Affiliated to Shandong University, Jinan, China
References (32)
Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. 10.1016/S0140-6736(10)62307-010.1016/S0140-6736(10)62307-0 ↗
3. 10.1200/JCO.2011.36.574210.1200/JCO.2011.36.5742 ↗
4. 10.1002/jso.293029010610.1002/jso.2930290106 ↗
5. 10.1002/cncr.2773410.1002/cncr.27734 ↗
6. 10.1016/j.pan.2012.11.31310.1016/j.pan.2012.11.313 ↗
7. 10.1016/j.cell.2009.01.00210.1016/j.cell.2009.01.002 ↗
8. 10.1038/nrg307410.1038/nrg3074 ↗
9. 10.1038/nrc393210.1038/nrc3932 ↗
10. Song S · Nat Rev · 2013 · 10 · 109
11. 10.1200/JCO.2009.24.934210.1200/JCO.2009.24.9342 ↗
12. 10.1073/pnas.101905510810.1073/pnas.1019055108 ↗
13. 10.1038/ncb221010.1038/ncb2210 ↗
14. 10.1074/jbc.M110.10782110.1074/jbc.M110.107821 ↗
15. Yu X · Ann Transl Med · 2015 · 3 · 297
16. 10.1371/journal.pone.009284710.1371/journal.pone.0092847 ↗
17. 10.1210/jc.2013-162910.1210/jc.2013-1629 ↗
18. 10.1016/j.atherosclerosis.2015.06.03110.1016/j.atherosclerosis.2015.06.031 ↗
19. 10.1016/j.gene.2014.11.03610.1016/j.gene.2014.11.036 ↗
20. 10.1016/j.bbrc.2017.01.00210.1016/j.bbrc.2017.01.002 ↗
21. 10.1016/j.bbrc.2017.01.00210.1016/j.bbrc.2017.01.002 ↗
22. 10.3727/096504016X1475628281938510.3727/096504016X14756282819385 ↗
23. 10.1016/j.gene.2016.06.05910.1016/j.gene.2016.06.059 ↗
24. 10.18632/oncotarget.895310.18632/oncotarget.8953 ↗
25. 10.1042/bse054012710.1042/bse0540127 ↗
26. 10.18632/oncotarget.765110.18632/oncotarget.7651 ↗
27. 10.1002/cam4.62610.1002/cam4.626 ↗
28. 10.1111/cas.1290410.1111/cas.12904 ↗
29. 10.1007/s13277-016-5445-810.1007/s13277-016-5445-8 ↗
30. 10.18632/oncotarget.1176810.18632/oncotarget.11768 ↗
31. 10.1038/bjc.2015.36610.1038/bjc.2015.366 ↗
32. 10.3892/ijo.2014.274310.3892/ijo.2014.2743 ↗